Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) is an oncology-focused drug development company.Our lead program is paxalisib, which is being developed to treat glioblastoma (GBM), the most common and aggressive form of primary brain cancer in adults. There are few treatment options for sufferers of GBM and around 65% of sufferers do not respond to currently available treatments. The condition affects around 133,000 people globally per annum and the potential addressable market is worth more than US$1 billion.Kazia's drug paxalisib, commenced recruitment to GBM AGILE, a pivotal study in glioblastoma, in January 2021. Eight additional studies are active in various forms of brain cancer. Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in August 2020. Kazia is also developing EVT801, , a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data for EVT801 has shown it to be active against a broad range of tumour types and has provided compelling evidence of synergy with immuno- oncology agents. A phase I study is expected to begin in CY2021. Competitive Advantages:- Lead program, paxalisib, sourced from the world's most successful cancer drug developer, Genentech- Experienced team with extensive backgrounds in big pharma and biotech- Around 65% of GBM sufferers do not respond to current treatments- Multiple shots on goal with collaborations progressing in other cancers; largely funded by participating hospitals

Website: kaziatherapeutics.com

Employees: 20 - 49

HQ: N/A

Location: Hornsby, NSW, AU

Revenue: Not Available

Kazia Therapeutics Limited is a biotechnology company that focuses on developing innovative cancer treatments. If you're looking for contact information for Kazia Therapeutics Limited, you've come to the right place. At ConnectPlex.ai, we provide AI-based B2B lead generation products that can help you connect with key decision-makers and professionals working at Kazia Therapeutics Limited. Our database contains millions of company records, and we can help you find the contact information you need to grow your business. Whether you're looking to collaborate with Kazia Therapeutics Limited or want to get in touch with their team for business opportunities, our platform can provide you with the necessary contact details. Our AI-powered algorithms ensure that the contact information is accurate and up-to-date, so you can be sure of getting in touch with the right person at Kazia Therapeutics Limited. With ConnectPlex.ai, you can take your business to the next level by connecting with the right people at the right time.

Kazia Therapeutics Limited is a biotechnology company focused on developing innovative treatments for cancer, with a particular emphasis on glioblastoma, the most common and aggressive form of primary brain cancer in adults. Based in Hornsby, Australia, the company's lead program is paxalisib, a drug that has shown promising results in treating glioblastoma, with a potential addressable market worth over US$1 billion. Kazia's drug development pipeline also includes EVT801, a small-molecule inhibitor of VEGFR3, which has shown activity against a broad range of tumor types and has the potential to be used in combination with immuno-oncology agents. Kazia's experienced team, which includes Chief Executive Officer & Managing Director James Garner and Chief Financial Officer Karen Krumeich, has extensive backgrounds in big pharma and biotech. The company's competitive advantages include its lead program, paxalisib, which was sourced from Genentech, the world's most successful cancer drug developer, as well as its multiple shots on goal with collaborations progressing in other cancers, largely funded by participating hospitals. With a strong pipeline and experienced leadership, Kazia Therapeutics Limited is poised to make a significant impact in the treatment of cancer.

Kazia Therapeutics is a company that creates drugs to treat cancer. They are working on a drug called paxalisib to treat a type of brain cancer called glioblastoma. This cancer is very aggressive and affects a lot of people. There aren't many treatments available, and most people don't respond to the ones that exist. Kazia's drug has shown promise in early studies and has been given special status by the US government to help it move through the development process faster. The company is also working on another drug called EVT801, which has shown potential in fighting many types of tumors. Kazia has a good team and has partnered with other hospitals and companies to develop their drugs. They have a good chance of success because their lead drug comes from a company that has made many successful cancer drugs before, and they have a lot of experience in the field.